Dendrite To Discuss Trends In Pharmaceutical Sales Force Automation
MORRISTOWN, NJ -- (INTERNET WIRE) -- 06/05/02 -- Dendrite (NASDAQ:
DRTE) today announced that Chief Technology Officer Marc Kustoff will lead workshops on "E-Sales and the use of E-Detailing in Sales Force Automation" at the IQPC E-Pharma Exchange 2002 June 12-13 at Cafe Royal in London.
On June 12 at 9:50 a.m. and 10:35 a.m., Kustoff will lead discussions on the impact of mobile technologies on managing field sales, the benefits of mobile data capture, and how real time data capture affects forecasting. The workshops will address the pros and cons of current tools and how they can be used to optimize sales forces.
Featuring attendance by more than 100 pharmaceutical professionals, the conference will review current industry topics and trends such as e-clinical trials, e-R&D, content and knowledge management, portal technology, and real time digital pharma. For more information on IQPC, visit www.iqpcexchange.com.
About Dendrite
Dendrite develops global pharmaceutical technology that helps clients strategically manage customer relationships to increase market share. The company creates unique, analytically driven solutions that enable pharmaceutical companies to influence prescriber behavior, thereby delivering a sustained competitive advantage. More than 80,000 pharmaceutical sales representatives and their managers from over 150 companies and 57 countries use Dendrite products and services. They represent 19 of the top 20 pharmaceutical companies. For more information, visit www.dendrite.com.
Note: Dendrite is a registered trademark of Dendrite International, Inc.
The foregoing contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The statements may be identified by such forward-looking terminology as "expect," "believe," "may," "will," "intend," "plan," and similar statements or variations. Such forward-looking statements are based on our current estimates and assumptions and involve certain significant risks and uncertainties, including those which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for our products, our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on major customers; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; acquisitions; events which may effect the U.S. and world economies; retention of key senior managers; our ability to manage our growth; the protection of our proprietary technology; unique characteristics of the consumer packaged goods industry; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements.
Contact: Erik Kopp, Dendrite
Phone: 908-541-5850
Email: erik.kopp@dendrite.com
DRTE) today announced that Chief Technology Officer Marc Kustoff will lead workshops on "E-Sales and the use of E-Detailing in Sales Force Automation" at the IQPC E-Pharma Exchange 2002 June 12-13 at Cafe Royal in London.
On June 12 at 9:50 a.m. and 10:35 a.m., Kustoff will lead discussions on the impact of mobile technologies on managing field sales, the benefits of mobile data capture, and how real time data capture affects forecasting. The workshops will address the pros and cons of current tools and how they can be used to optimize sales forces.
Featuring attendance by more than 100 pharmaceutical professionals, the conference will review current industry topics and trends such as e-clinical trials, e-R&D, content and knowledge management, portal technology, and real time digital pharma. For more information on IQPC, visit www.iqpcexchange.com.
About Dendrite
Dendrite develops global pharmaceutical technology that helps clients strategically manage customer relationships to increase market share. The company creates unique, analytically driven solutions that enable pharmaceutical companies to influence prescriber behavior, thereby delivering a sustained competitive advantage. More than 80,000 pharmaceutical sales representatives and their managers from over 150 companies and 57 countries use Dendrite products and services. They represent 19 of the top 20 pharmaceutical companies. For more information, visit www.dendrite.com.
Note: Dendrite is a registered trademark of Dendrite International, Inc.
The foregoing contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The statements may be identified by such forward-looking terminology as "expect," "believe," "may," "will," "intend," "plan," and similar statements or variations. Such forward-looking statements are based on our current estimates and assumptions and involve certain significant risks and uncertainties, including those which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for our products, our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on major customers; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; acquisitions; events which may effect the U.S. and world economies; retention of key senior managers; our ability to manage our growth; the protection of our proprietary technology; unique characteristics of the consumer packaged goods industry; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements.
Contact: Erik Kopp, Dendrite
Phone: 908-541-5850
Email: erik.kopp@dendrite.com
This website uses cookies to ensure you get the best experience on our website. Learn more